Abstracts tagged "Sjögren’s syndrome"

Abstract Number: 2303 • ACR Convergence 2025
Metabolic impact of low dose IL‐2 therapy for primary Sjögren’s Disease in a double‐blind, randomized clinical trial
Ruiling Feng, Bo Huang and Yuebo Jin, Peking University People’s Hospital, Beijing, China (People's Republic)
Background/Purpose: Low-dose interleukin 2 (Ld-IL2) is increasingly being explored as an immune-modulating treatment for autoimmune diseases which mainly affect T cell subsets. This study investigates…
Abstract Number: 2047 • ACR Convergence 2025
Trends in Lung Transplant Listing Outcomes in Connective Tissue Disease associated Interstitial Lung Disease (CTD-ILD) Across Two Decades
Sambhawana Bhandari¹, Derek E. Byers¹ and Deepali Sen², ¹Washington University in St. Louis School of Medicine, St. Louis, ²Washington University in St Louis, Chesterfield, MO
Background/Purpose: Lung transplantation represents a potential life-extending therapy for patients with advanced CTD-ILD. This study aims to characterize lung transplant listing outcomes among CTD-ILD patients…
Abstract Number: 1404 • ACR Convergence 2025
Higher cardiovascular risk and lymphoma development in primary Sjögren’s Syndrome with extraglandular involvement
Teresa Blázquez Sánchez¹, Antía García Fernández¹, Jorge Mairal Monesma², Arantxa Torres Roselló³, Elena Heras Recuero⁴, Raquel Largo Carazo⁵, Juan Antonio Martínez López⁶ and Miguel A. González-Gay⁷, ¹Fundacion Jiménez Díaz, Madrid, Madrid, Spain, ²Instituto de Investigacion Fundación Jiménez Díaz, Madrid, Spain, ³Fundacion Jiménez Díaz, Madrid, Spain, ⁴Hospital Fundacion Jimenez Dias, Madrid, Spain, ⁵Instituto de Investigacion Fundacion Jiménez Díaz, Madrid, Spain, ⁶Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain, ⁷Department of Rheumatology and Joint and Bone Research Unit, Hospital Universitario Fundación Jiménez Díaz, and Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Madrid, Spain, and Medicine and Psychiatry Department, University of Cantabria, Santander, Spain
Background/Purpose: Primary Sjögren’s syndrome (pSS) can have a systemic involvement with extraglandular manifestations, which are associated with more severe disease and with higher risk of…
Abstract Number: 1387 • ACR Convergence 2025
Demographic and Clinical Characteristics of Patients Diagnosed With Sjögren’s Disease Using Electronic Health Records and Linked Claims Data From the US Excellence Network in RheumatoloGY (ENRGY) Practice-Based Research Network
Jeffrey Curtis¹, Emily Holladay², Antton Egana³, Anjana Lalla³, Yujie Su⁴, Fenglong Xie⁵, Amy Mudano⁴, Shanette Daigle⁴ and Sara McCoy⁶, ¹Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ²University of Alabama at Birmingham, Edmond, OK, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Foundation for Advancing Science, Technology, Education and Research (FASTER), Hoover, AL, ⁵The University of Alabama at Birmingham, Birmingham, AL, ⁶University of Wisconsin–Madison, Madison, WI
Background/Purpose: Sjögren’s disease (SjD) is a chronic autoimmune disease characterized by systemic symptoms such as dryness, fatigue, musculoskeletal pain, and extraglandular manifestations. SjD may overlap…
Abstract Number: 0903 • ACR Convergence 2025
Ianalumab‘s dual mode of action: targeting B cells through enhanced B cell depletion and blockade of B cell-activating factor receptor signaling
Catherine Wioland¹, Corinne Vedrine², Caroline Walter¹, Fanny Marque², Thomas Dannequin², Melanie Cecci¹, David Buffet¹, Cindy Schmid¹, Elena Degl'Innocenti¹, Gautier Robert¹, Grazyna Wieczorek¹, David Schubert¹, Catriona Paape¹ and Isabelle Isnardi³, ¹Novartis Pharma AG, Basel, Switzerland, ²Novartis Pharma AG, Basel, Basel-Stadt, Switzerland, ³Novartis, Gueberschwihr, France
Background/Purpose: B cells are key players in the pathogenesis of Sjögren’s disease (SjD) and other systemic auto-immune diseases, supporting B cell depletion as an attractive…
Abstract Number: 0507 • ACR Convergence 2025
Diagnostic performance of the lacrimal and salivary gland ultrasound in patients with primary Sjogren’s disease of recent onset versus sicca controls.
Rosa Elena Cervantes¹, Carina Soto-Fajardo², Fabian Carranza³, Gabriela Hernandez-Molina⁴, Narlly Ruíz Quintero⁵, Daniela Rojas Abarca⁶, Ana Mora⁷, Ada Rocío Morales Meza⁶, Carlos Montiel Castañeda⁸, Angela Maldonado Luna⁹, Fabiola Sánchez Zamudio⁶ and Carlos Pineda², ¹National Institute of Rehabilitation "Luis Guillermo Ibarra Ibarra"", Mexico City, Distrito Federal, Mexico, ²National Rehabilitation Institute " Luis Guillermo Ibarra Ibarra ", Mexico City, Mexico, ³National Rehabilitation Institute " Luis Guillermo Ibarra Ibarra ", Ciudad de México, Mexico, ⁴Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Federal District, Mexico, ⁵Instituto Nacional de Ciencias Medicas y Nutricion, México, city, Distrito Federal, Mexico, ⁶National Institute of Rehabilitation "Luis Guillermo Ibarra Ibarra", Mexico, City, Distrito Federal, Mexico, ⁷National Rehabilitation Institute " Luis Guillermo Ibarra Ibarra ", Mexico, Mexico, ⁸National Institute of Rehabilitation "Luis Guillermo Ibarra Ibarra", México, city, Distrito Federal, Mexico, ⁹Instituto Nacional de Ciencias Medicas y Nutricion, Mexico, City, Estado de México, Mexico
Background/Purpose: Sjögren's disease (SjD) is a chronic systemic autoimmune disease primarily affecting the exocrine glands. There is an increasing use of salivary gland ultrasound in…
Abstract Number: 2302 • ACR Convergence 2025
Clustering by ESSPRI and PROMIS domain measures defines distinct subtypes and facilitates longitudinal assessment of patients with Sjogren’s disease
Thomas Grader-Beck¹, Jennifer Reed², Priya Patel³, Ji Soo Kim⁴ and Alan Baer⁵, ¹Johns Hopkins, Reisterstown, MD, ²Johns Hopkins, Freeland, MD, ³Johns Hopkins, Annville, PA, ⁴Johns Hopkins, Baltimore, MD, ⁵Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Patient-reported outcomes (PROs) measure a patient’s health-related quality of life. The role of ESSPRI and PROMIS measures in identifying subsets of patients with Sjogren’s…
Abstract Number: 2025 • ACR Convergence 2025
Spectrum of Autoantibodies in CNS Demyelinating Diseases: Clinical, Laboratory and Imaging Associations
Anna Rapti¹, Dimitris Karathanasis², Sylvia Raftopoulou¹, Charalampos Skarlis¹, Clio Mavragani¹ and Maria Eleftheria Evangelopoulos², ¹Department of Physiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ²First Department of Neurology, School of Medicine, Eginition Hospital, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece
Background/Purpose: Systemic autoimmune diseases (SADs) may present with CNS demyelination, mimicking multiple sclerosis (MS), though driven by distinct immunopathogenic mechanisms. While ANA and aPL are…
Abstract Number: 1403 • ACR Convergence 2025
Treatment of sleep apnoea syndrome in patients with primary Sjögren’s disease improves symptoms and activity of disease
Anna Kuhn¹, Magdalena Seng², Björn Christian Frye³, Sebastian Fähndrich³, Lydia Vollmer³, Jacques-eric GOTTENBERG⁴, Florian Kollert⁵, Reinhard Voll⁶ and Stephanie Finzel⁷, ¹¹University Medical Center, Department of Rheumatology and Clinical Immunology, Freiburg, Germany, Freiburg, Germany, ²¹University Medical Center, Department of Rheumatology and Clinical Immunology, Freiburg, Germany; ²University Medical Center, Department of Radiology and Nuclear medicine, Basel, Switzerland, Freiburg, Germany, ³³University Medical Center, Department of Pulmonology, Freiburg, Germany, Freiburg, Germany, ⁴Hautepierre Hospital, STRASBOURG, Alsace, France, ⁵¹University Medical Center, Department of Rheumatology and Clinical Immunology, Freiburg, Germany; Department of Rheumatology and Immunology, Inselspital, Bern University Hospital, University of Bern, Bern; Switzerland Department of Rheumatology, University Hospital Basel, Basel, Switzerland, Basel, Switzerland, ⁶University Medical Center Freiburg, Freiburg, Germany, ⁷Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
Background/Purpose: About 70% of patients with primary Sjögren's disease (pSjD) suffer from fatigue. Fatigue is associated with functional deficits(1), leading to anxiety, depression and reduced…
Abstract Number: 1386 • ACR Convergence 2025
Characterization and Progression of Localized Amyloidosis in Sjogren’s Syndrome: Evidence Long-Term (1995-2025) Follow-Up of a Cohort compared to Literature Review.
Hoang Nguyen¹, Philip Moresco², Antoine Chiu², Asha Patnaik³ and Peter Gorevic⁴, ¹Stony Brook University-Renaissance School of Medicine- Department of Rheumatology, Jamaica, NY, ²Stony Brook University -Renaissance School of Medicine, Stony Brook, NY, ³Stony Brook University Hospital, Stony Brook, NY, ⁴Stony Brook University, Stony Brook, NY
Background/Purpose: -Sjogren’s syndrome (SS) is a chronic autoimmune disorder, defined by keratoconjunctivitis sicca (KCS), specific serologies, and a significant risk of extra-exocrine disease manifestations and…
Abstract Number: 0899 • ACR Convergence 2025
Altered B cell Subsets Shared in Immune Checkpoint Inhibitor Associated Sicca Syndrome and Sjogren’s Disease
Caroline Atlas¹, Balakrishnan Kamaraj¹, Omid Jamshidi¹, Adam Mor¹, Yevgeniya Gartshteyn², Teja Kapoor³ and Robert Winchester¹, ¹Columbia University, New York, NY, ²Columbia University Medical Center, Glen Rock, NJ, ³Columbia University Irving Medical Center, New York, NY
Background/Purpose: Sicca symptoms may develop in the setting of immune checkpoint inhibitor (ICI) therapy and are clinically indistinguishable from those encountered in Sjogren’s disease (SjD).…
Abstract Number: 0506 • ACR Convergence 2025
Discovery-based Identification of Non-canonical Autoantibody Specificities in Ro Seronegative Sjögren’s Disease Using High-content Human Proteome Arrays
Songyuan Yao¹, Christina Lawrence¹, Hope Christakos², Charmaine Lopez-Davis¹, Bhuwan Khatri¹, Tommi C. Taylor¹, Astrid Rasmussen¹, Kiely Grundahl², R Hal Scofield¹, Blake M. Warner³, Judith James¹, Joel Guthridge¹, Christopher J. Lessard¹ and A. Darise Farris¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, ³National Institutes of Health, Bethesda, MD
Background/Purpose: Clinical tests for Sjögren’s disease (SjD) often overlook Ro-seronegative (RoNeg) cases, leading to delayed or missed diagnoses. Identifying additional serum autoantibodies could improve diagnostic…
Abstract Number: 2301 • ACR Convergence 2025
Use of lived experiences in childhood Sjogren Disease to develop outcome measures for an N-of-1 treatment trial.
Sara M. Stern¹, Angela Merritt², Ludovic Trinquart³, Emma Barnboym⁴, Michelle LeeBravatti³, Suzy Richins⁵, Tressie L. Rollins⁵, Hanna M. Salzman⁵, Marisha Palm³, Cortney M. Wieber⁶, Hermine Brunner⁷ and Nora G. Singer⁸, ¹University of Utah, Salt Lake City, UT, ²Cincinnati Childrens Hospital Medical Center, Cincinnati, OH, ³Tufts University School of Medicine, Boston, MA, ⁴The MetroHealth System at Case Western Reserve University School of Medcine, Cleveland, OH, ⁵Pediatric Rheumatology, University of Utah, Salt Lake City, UT, ⁶Institute for Clinical Research and Health Policy Studies (ICRHPS) and CTSI, Tufts School of Medicine, Boston, MA, ⁷Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸The MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: Childhood Sjogren Disease (cSjD) is a rare disease that presents with a wide variety of symptoms. Compared to adult SjD, cSjD more frequently manifests…
Abstract Number: 2017 • ACR Convergence 2025
Baseline and 2-year Follow-up of Pulmonary Function Among CTD-ILD Subtypes
Ivana Ilic, Anchal Sabharwal, Galina Marder and Sonali Narain, Northwell, Great Neck
Background/Purpose: Interstitial lung disease is a major cause of morbidity and mortality in patients with connective tissue disease (CTD-ILD). Evaluation of ILD severity and progression…
Abstract Number: 1402 • ACR Convergence 2025
Understanding Fatigue Through Patients’ Eyes: Development of a Novel Questionnaire Capturing the Complexity of Real-Life Fatigue in Sjögren’s Disease
Saviana Gandolfo¹, Flavia Riccio², Mariachiara Visconti³, Corrado Parlati³, Nicola Della Rossa⁴, Enrico Tirri⁵ and Francesco Ciccia³, ¹Rheumatology Unit, Ospedale del mare, Naples, Naples, Naples, Italy, ²Rheumatology Section, University of Campania L. Vanvitelli, Naples, Italy, Napoli, Italy, ³Rheumatology Section, University of Campania L. Vanvitelli, Naples, Italy, Naples, Italy, ⁴Rheumatology Section, University of Campania L. Vanvitelli, Naples, Italy, Naples, ⁵Rheumatology Unit, Ospedale del mare, Naples, Italy, Naples, Italy
Background/Purpose: Fatigue is one of the most frequent, debilitating and impactful symptoms for patients with Sjögren's Disease (SjD), and one of the most challenging to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].